Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with cystic fibrosis confirmed by sweat or genetic test~* Patient with clinical signs of exacerbation (increased cough, sputum (abundance, purulence), fever, anorexia, weight loss and FEV1) or acute exacerbations (defined at the clinician's discretion )~* FEV1 ≥ 25%~* Pseudomonas aeruginosa chronic carriers (defined by at least two antipyocyanic precipitation arcs or at least 3 successive positive ECBCs over a period of 18 months)~* Patient who received at least 1 IV course of antibiotics in the 18 months prior to inclusion.~Exclusion Criteria:~* Severe exacerbation (requiring hospitalization due to severe amputation of FEV 1, oxygen deficiency, or severe impairment of general health).~* Patient with 3rd antibiotic therapy (triple therapy)~* Patient colonized in Burkholderia cepacia~* Patient colonized by an atypical mycobacterium~* Patient with pulmonary transplant or transplant~  * chronic tinnitus~ * patient using hearing aid~* Hypersensitivity to tobramycin and other antibiotics of the aminoglycoside family~* Cirrhosis of Grades B and C according to the Child-Pugh Classification~* Myasthenia gravis~* Simultaneous administration of another aminoglycoside~* Renal failure~* Recent history of severe hemoptysis (within 2 months before inclusion)~* Patient participating simultaneously in another clinical study conducted on a drug for the duration of its participation in this research

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard cure (Type: EXPERIMENTAL): Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
- Short cure (Type: EXPERIMENTAL): antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care

Based on this trial design, predict the completion outcome and termination type (if applicable).